{"title":"MTHFD1 Deficiency in Two Unrelated Children: Highlights on Phenotypic Spectrum and Response to Folic Acid Therapy.","authors":"Fajer Altammar, Haidy Elsayed, Mohamed Elshinawy, Waleed Al-Herz","doi":"10.1097/MPH.0000000000003238","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Methylene-tetrahydrofolate dehydrogenase 1 (MTHFD1) deficiency is a rare inborn error of immunity (IEI) involving defects in folate metabolism. It can present with combined immunodeficiency and variable phenotypic features, including recurrent bacterial infections, megaloblastic anemia, and failure to thrive.</p><p><strong>Methods: </strong>We describe 2 unrelated Kuwaiti children with MTHFD1 deficiency caused by a homozygous pathogenic variant [c.517C>T (Arg173Cys)].</p><p><strong>Results: </strong>Both cases presented with unexplained megaloblastic anemia, recurrent sinopulmonary infections, failure to thrive, and developmental delay. The first patient, a 10-year-old girl, was diagnosed with combined immunodeficiency and autoimmune thyroiditis. Treatment with folic acid resulted in significant clinical improvement. The second patient, a 3-year-old girl, presented with sepsis secondary to progressive lobar pneumonia and bone marrow failure. Despite intensive treatment, including broad-spectrum antibiotics, antifungals, IVIG, and dexamethasone for suspected hemophagocytic lymphohistiocytosis, she developed severe complications and passed away on day 18 of PICU admission.</p><p><strong>Conclusion: </strong>As there is no specific clinical or laboratory phenotype for most IEIs, we emphasize the importance of molecular diagnosis through urgent genetic testing in patients with suspected MTHFD1 deficiency. Precision therapy with prompt folate or folinic acid supplementation can significantly improve outcomes, as evidenced by the survival of one patient with minimal intervention.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e241-e244"},"PeriodicalIF":0.9000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology/Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPH.0000000000003238","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: Methylene-tetrahydrofolate dehydrogenase 1 (MTHFD1) deficiency is a rare inborn error of immunity (IEI) involving defects in folate metabolism. It can present with combined immunodeficiency and variable phenotypic features, including recurrent bacterial infections, megaloblastic anemia, and failure to thrive.
Methods: We describe 2 unrelated Kuwaiti children with MTHFD1 deficiency caused by a homozygous pathogenic variant [c.517C>T (Arg173Cys)].
Results: Both cases presented with unexplained megaloblastic anemia, recurrent sinopulmonary infections, failure to thrive, and developmental delay. The first patient, a 10-year-old girl, was diagnosed with combined immunodeficiency and autoimmune thyroiditis. Treatment with folic acid resulted in significant clinical improvement. The second patient, a 3-year-old girl, presented with sepsis secondary to progressive lobar pneumonia and bone marrow failure. Despite intensive treatment, including broad-spectrum antibiotics, antifungals, IVIG, and dexamethasone for suspected hemophagocytic lymphohistiocytosis, she developed severe complications and passed away on day 18 of PICU admission.
Conclusion: As there is no specific clinical or laboratory phenotype for most IEIs, we emphasize the importance of molecular diagnosis through urgent genetic testing in patients with suspected MTHFD1 deficiency. Precision therapy with prompt folate or folinic acid supplementation can significantly improve outcomes, as evidenced by the survival of one patient with minimal intervention.
背景和目的:亚甲基四氢叶酸脱氢酶1 (MTHFD1)缺乏症是一种罕见的先天性免疫缺陷(IEI),涉及叶酸代谢缺陷。它可以表现为联合免疫缺陷和可变表型特征,包括复发性细菌感染,巨幼细胞性贫血和不能茁壮成长。方法:我们描述了2名由纯合致病变异引起的无亲缘关系的科威特儿童MTHFD1缺乏症[c]。517 c > T (Arg173Cys)]。结果:两例患儿均表现为不明原因的巨幼细胞性贫血、复发性肺感染、发育迟缓和发育迟缓。第一位患者是一名10岁的女孩,她被诊断为联合免疫缺陷和自身免疫性甲状腺炎。用叶酸治疗可显著改善临床症状。第二例患者为一名3岁女孩,表现为败血症继发于进行性大叶性肺炎和骨髓衰竭。尽管患者接受了广谱抗生素、抗真菌药物、免疫球蛋白和地塞米松治疗,但仍出现严重并发症,于PICU入院第18天去世。结论:由于大多数iei没有特定的临床或实验室表型,我们强调通过紧急基因检测对疑似MTHFD1缺乏症患者进行分子诊断的重要性。及时补充叶酸或亚叶酸酸的精确治疗可以显著改善预后,一名患者在最小干预下的生存率证明了这一点。
期刊介绍:
Journal of Pediatric Hematology/Oncology (JPHO) reports on major advances in the diagnosis and treatment of cancer and blood diseases in children. The journal publishes original research, commentaries, historical insights, and clinical and laboratory observations.